Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Aclaris Therapeutics (ACRS) Operating Margin: 2017-2025

Historic Operating Margin for Aclaris Therapeutics (ACRS) over the last 8 years, with Sep 2025 value amounting to -519.82%.

  • Aclaris Therapeutics' Operating Margin fell 27889.00% to -519.82% in Q3 2025 from the same period last year, while for Sep 2025 it was -973.93%, marking a year-over-year decrease of 80294.00%. This contributed to the annual value of -758.18% for FY2024, which is 44663.00% down from last year.
  • Per Aclaris Therapeutics' latest filing, its Operating Margin stood at -519.82% for Q3 2025, which was up 49.82% from -1,035.90% recorded in Q2 2025.
  • Over the past 5 years, Aclaris Therapeutics' Operating Margin peaked at -23.03% during Q4 2023, and registered a low of -1,702.25% during Q2 2023.
  • For the 3-year period, Aclaris Therapeutics' Operating Margin averaged around -784.07%, with its median value being -789.45% (2024).
  • The largest annual percentage gain for Aclaris Therapeutics' Operating Margin in the last 5 years was 123,753bps (2024), contrasted with its biggest fall of 105,910bps (2024).
  • Over the past 5 years, Aclaris Therapeutics' Operating Margin (Quarterly) stood at -1,525.18% in 2021, then spiked by 115,012bps to -375.07% in 2022, then surged by 35,203bps to -23.03% in 2023, then slumped by 105,910bps to -1,082.13% in 2024, then crashed by 27,889bps to -519.82% in 2025.
  • Its Operating Margin stands at -519.82% for Q3 2025, versus -1,035.90% for Q2 2025 and -1,242.89% for Q1 2025.